Filing Analysis
Clene Inc. filed an 8-K to announce its second quarter 2026 financial results and recent operating highlights for the period ended June 30, 2026.
📋 Key Facts
- Report date: August 14, 2026
- Reporting period: Second Quarter 2026 (ended June 30, 2026)
- The filing includes a press release regarding financial results and operating highlights as Exhibit 99.1.
- CEO Robert Etherington signed the report.
Clene Inc. released an updated corporate presentation and announced the inclusion of biomarker analyses in its upcoming NDA submission for accelerated approval regarding ALS treatment.
📋 Key Facts
- Released updated Corporate Presentation on August 10, 2026 (Exhibit 99.1).
- Announced that biomarker analyses will be included in the Company's NDA submission supporting ALS accelerated approval (Exhibit 99.2).
- The filing includes disclosures under Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events).
Clene Inc. (CLNN) filed an 8-K on May 22, 2026 disclosing an amendment to its August 2025 senior secured convertible promissory notes, deferring $150,000/month principal and interest payments and extending maturity to August 13, 2027. The filing also covers the 2026 Annual Meeting results, including stockholder approval of a 1,000,000-share increase to the Amended 2020 Stock Plan and ratification of Deloitte & Touche LLP as auditor. The note amendment signals potential near-term liquidity stress, as the company sought to defer scheduled debt service obligations.
🚩 Red Flags
- Deferral of $150,000/month debt service payments suggests the company could not meet near-term cash obligations — a strong liquidity warning signal.
- Notes are senior secured and convertible, meaning noteholders have priority claims on assets and potential equity dilution leverage.
- Counterparties include named individuals (Glenn and Shelina Way), raising potential related-party transaction concerns.
- Multiple 8-K items in a single filing (Items 1.01, 5.02, 5.07) is an escalating red flag per classification guidelines.
- 1,000,000 additional shares authorized under the stock plan adds dilution pressure on a micro-cap company with a small float (total votes cast suggest a small share base).
- Change-in-control trigger in the maturity clause could accelerate debt repayment, creating risk in any M&A scenario.
- High broker non-votes (3,057,461 vs. ~4.7M total votes on routine matters) indicate limited institutional engagement.
📋 Key Facts
- On May 18, 2026, Clene amended senior secured convertible promissory notes originally issued August 13, 2025 with AE Capital Limited, A Global Chorus Foundation, and Glenn and Shelina Way.
- Amendment extends maturity date to the earlier of August 13, 2027 or a change-in-control event.
- Monthly aggregate principal and accrued interest payments of $150,000/month, previously scheduled to commence September 13, 2026, were deferred — full balance now due at maturity.
- Annual Meeting held May 21, 2026; stockholders approved all four proposals.
- Amended 2020 Stock Plan approved to increase shares reserved for issuance by 1,000,000 shares (par value $0.0001).
- Deloitte & Touche LLP ratified as independent auditor for fiscal year 2026 with 7,737,513 votes for vs. 11,372 against.
- Class III directors Robert Etherington, Shalom Jacobovitz, and Alison H. Mosca elected through 2029 annual meeting.
- Significant broker non-votes of 3,057,461 on non-routine proposals suggest institutional holder passivity.
- Filing covers Items 1.01, 5.02, 5.07, and 9.01 — four separate 8-K items in one filing.
Clene Inc. (CLNN) entered into a Second Amendment to its senior secured convertible promissory notes on May 11, 2026, extending the maturity date to August 13, 2027 and deferring $1,000,000/month principal and interest payments that were set to begin September 13, 2026. The amendment involves multiple related parties, including a note holder controlled by a sitting board director and another controlled by a board member of the Company's subsidiary. The filing also includes Q1 2026 financial results under Item 2.02.
🚩 Red Flags
- This is the SECOND amendment to notes issued only in December 2024 — repeated restructuring signals persistent liquidity stress
- Full deferral of $1,000,000/month debt service payments is a material concession by lenders, suggesting the Company cannot meet scheduled obligations
- All three note holders have direct or indirect related-party relationships with Company insiders (a sitting independent director and a subsidiary board member), raising governance and arm's-length negotiation concerns
- La Scala and 4Life are both controlled by David Lisonbee, concentrating counterparty exposure among insiders
- Multiple 8-K items (1.01, 2.02, 9.01) filed simultaneously — a complexity escalator
- Change-of-control maturity trigger could accelerate full repayment in an M&A scenario, creating a potential overhang
📋 Key Facts
- Second Amendment to senior secured convertible promissory notes executed May 11, 2026
- Notes originally issued December 20, 2024; previously amended August 13, 2025 — this is the second amendment in roughly 17 months
- Maturity date extended to the earlier of August 13, 2027 or a change-of-control event
- Monthly aggregate principal and accrued interest payments of $1,000,000/month, previously scheduled to commence September 13, 2026, were fully deferred until the new maturity date
- Three holders: Kensington Clene 2024 LLC, 4Life Research LLC, and La Scala Investments LLC
- Kensington is controlled by Alison Mosca, an independent director of the Company — direct related-party conflict
- 4Life Research has existing license and supply agreements with the Company
- David Lisonbee, co-founder and chairman of 4Life, sits on the board of Clene Nanomedicine Inc. (wholly-owned subsidiary); La Scala Investments is also controlled by Lisonbee
- Filing simultaneously covers Item 1.01 (material agreement), Item 2.02 (Q1 2026 earnings), and Item 9.01 (exhibits) — three 8-K items in one filing
- Full text of Second Amendment incorporated by reference to 10-Q filed May 14, 2026
Clene Inc. entered into an underwriting agreement with Canaccord Genuity to sell 1,000,000 shares of common stock at $7.00 per share. The offering is expected to generate approximately $6.4 million in net proceeds to fund the New Drug Application (NDA) filing for lead candidate CNM-Au8 and Phase 3 clinical trials.
🚩 Red Flags
- Dilution of existing shareholders through the issuance of 1,000,000 new shares.
- Relatively short lock-up period of only 60 days for insiders.
📋 Key Facts
- Offering of 1,000,000 shares of common stock at a price of $7.00 per share.
- Estimated net proceeds of approximately $6.4 million after underwriting discounts and $140,000 in expenses.
- Underwriting commission set at 6.5% of gross proceeds.
- Proceeds earmarked for CNM-Au8 NDA filing, Phase 3 trials, manufacturing expansion, and potential commercialization.
- 60-day lock-up period for the company, executive officers, and directors.
- Canaccord Genuity LLC is the sole bookrunner; Maxim Group LLC and D. Boral Capital LLC are financial advisors.
Clene Inc. announced it will seek accelerated approval from the FDA for its ALS drug candidate, CNM-Au8, following a successful Type C meeting. The FDA indicated that neurofilament light (NfL) could potentially serve as a surrogate endpoint, allowing for an NDA submission targeted for Q3 2026.
🚩 Red Flags
- The FDA's language is non-committal, stating data 'may be' capable of supporting a submission.
- The company must still prove the magnitude of NfL change is 'reasonably likely to predict clinical benefits'.
- The confirmatory Phase 3 trial will not begin until after the NDA is submitted (Q1 2027).
📋 Key Facts
- FDA stated Clene's proposed data 'may be capable of supporting' an NDA submission under the accelerated approval pathway.
- The company intends to submit the NDA in Q3 2026.
- NfL (neurofilament light) is being used as a surrogate endpoint to predict clinical benefit.
- A Phase 3 confirmatory study is planned to commence in Q1 2027.
- Submission data includes Phase 2 HEALEY ALS Platform Trial, RESCUE-ALS Trial, and NIH-sponsored Expanded Access Protocol data.
- CNM-Au8 has previously received Orphan Drug Designation for ALS.
Clene Inc. entered into an $8.0 million subaward agreement with New York University for the third year of a four-year, $45.1 million NIH grant. The funding supports the company's Expanded Access Program for its ALS treatment candidate, CNM-Au8.
📋 Key Facts
- Agreement signed March 13, 2026, with New York University (NYU) as the prime awardee.
- The subaward provides up to $8.0 million for the period from September 1, 2025, to August 31, 2026.
- This is the third year of a $45.1 million NIH grant originally announced in October 2023.
- The grant supports the treatment of amyotrophic lateral sclerosis (ALS) under the Accelerating Access to Critical Therapies for ALS Act.
- Funding is disbursed via monthly reimbursement invoices.
- The agreement includes a 30-day termination clause for either party.
Clene Inc. reported its full year 2025 operating and financial results on March 12, 2026. The filing serves as a formal disclosure of the company's year-end performance via an attached press release.
📋 Key Facts
- The filing was made on March 12, 2026, covering the fiscal year ended December 31, 2025.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- A press release detailing the financial results was included as Exhibit 99.1.
- The company is listed on the Nasdaq Capital Market under the ticker CLNN.
Clene Inc. issued a press release and a letter to stockholders on February 24, 2026, detailing upcoming 2026 catalysts for its lead drug candidate, CNM-Au8. The filing serves as a routine investor update regarding the company's clinical and operational outlook.
📋 Key Facts
- Issued press release on February 24, 2026.
- Highlighted upcoming 2026 catalysts for lead candidate CNM-Au8.
- The disclosure was made under Item 8.01 (Other Events).
- Incorporated Exhibit 99.1 (Press Release) by reference.
Clene Inc. entered into a securities purchase agreement to sell common stock and warrants to institutional investors for approximately $6.0 million in gross proceeds. The funds are intended to support the clinical development of its lead drug candidate, CNM-Au8.
🚩 Red Flags
- Significant dilution potential due to the issuance of over 3.7 million warrants.
- Warrant exercise price escalators linked to FDA milestones and stock price performance, which can create downward pressure on share price upon exercise.
📋 Key Facts
- Offering size: Approximately $6.0 million in aggregate gross proceeds.
- Securities sold: 928,333 shares of common stock and two tranches of warrants (Series A and Series B).
- Warrant terms: Series A Warrants for up to 1,114,000 shares; Series B Warrants for up to 2,599,333 shares.
- Pricing: Units sold at $6.50 per unit; warrants are immediately exercisable at $6.00 per share.
- Use of proceeds: Clinical development of CNM-Au8, regulatory activities, and general corporate purposes.
- Placement Agent: BTIG, LLC (6.0% cash fee plus expense reimbursement).
Clene Inc. announced the release of additional CNM-Au8 biomarker data intended to support a potential New Drug Application (NDA) filing in anticipation of an upcoming meeting with the FDA.
📋 Key Facts
- Announced additional CNM-Au8 biomarker data on January 12, 2026.
- Data is being used to support a potential New Drug Application (NDA) filing.
- The company is preparing for an upcoming in-person meeting with the U.S. Food and Drug Administration (FDA).
Clene Inc. provided a clinical program update regarding its CNM-Au8 treatment for Amyotrophic Lateral Sclerosis (ALS) via a conference call and webcast on December 3, 2025.
📋 Key Facts
- The company hosted a webcast/conference call to provide an update on the CNM-Au8 program in ALS.
- Information was disclosed under Item 7.01 (Regulation FD Disclosure).
- An updated presentation regarding the clinical program was furnished as Exhibit 99.1.
Clene Inc. announced statistically significant ALS biomarker results for its drug candidate CNM-Au8, which the company believes supports an accelerated approval pathway.
📋 Key Facts
- Date of announcement: December 3, 2025.
- Subject matter: Statistically significant amyotrophic lateral sclerosis (ALS) biomarker results.
- Strategic goal: Supporting an accelerated approval pathway for CNM-Au8.
Clene Inc. filed an 8-K to announce its third quarter 2025 financial results and recent operating highlights for the period ended September 30, 2025.
📋 Key Facts
- Report date: November 13, 2025
- Reporting period: Third Quarter 2025 (ended September 30, 2025)
- The filing includes a press release regarding financial results and operating highlights as Exhibit 99.1.
- The company is listed on the Nasdaq Capital Market under ticker CLNN.
Clene Inc. has filed a prospectus supplement under its existing equity distribution agreement with Canaccord Genuity LLC to offer up to $18,880,000 in additional common stock. This follows a previous sale of approximately $6.1 million under the same agreement.
🚩 Red Flags
- Continuous equity dilution: The company is actively utilizing an 'at-the-market' style distribution agreement to raise capital, which typically results in significant shareholder dilution.
- High frequency of offerings: Having sold $6.1M and now seeking another $18.8M suggests a high burn rate or continuous need for cash infusion.
📋 Key Facts
- Company entered into an Equity Distribution Agreement on April 28, 2025, with Canaccord Genuity LLC as placement agent.
- The original aggregate offering size was up to $25,000,000.
- Approximately $6,119,859 in common stock has already been sold under the agreement.
- On October 17, 2025, a prospectus supplement was filed for an additional $18,880,000 of Common Stock.
- The offering involves common stock and warrants (CLNNW) listed on Nasdaq.
Clene Inc. released an updated corporate presentation containing preliminary, unaudited financial information as of September 30, 2025, and subsequent equity proceeds.
🚩 Red Flags
- Information is preliminary, unaudited, and subject to material adjustments during audit procedures.
📋 Key Facts
- Released updated Corporate Presentation on October 14, 2025.
- Provided preliminary unaudited balance of cash and cash equivalents as of September 30, 2025.
- Disclosed gross proceeds raised via an Equity Distribution Agreement (ATM Agreement) between Sept 30, 2025, and Oct 14, 2025.
- Management cautioned that actual results may vary due to incomplete financial closing procedures.
Clene Inc. announced the presentation of new clinical data at the ECTRIMS 2025 congress regarding its product CNM-Au8. The data suggests improvement in brain energy metabolism for multiple sclerosis patients.
📋 Key Facts
- Presented new clinical data at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2025).
- Clinical data focuses on CNM-Au8 improving brain energy metabolism in multiple sclerosis patients.
- The announcement was made via press release on September 25, 2025.
Clene Inc. has filed a prospectus supplement under its existing equity distribution agreement with Canaccord Genuity LLC to offer an additional $6,280,000 in common stock. This follows previous sales of approximately $3.7 million under the same agreement.
🚩 Red Flags
- Ongoing use of At-The-Market (ATM) style equity distribution suggests continuous need for liquidity.
- Potential dilution for existing shareholders through the issuance of new common stock.
📋 Key Facts
- Company entered into an Equity Distribution Agreement with Canaccord Genuity LLC on April 28, 2025.
- The total aggregate offering price under the original agreement is up to $25,000,000.
- Approximately $3,706,213 in common stock has been sold to date.
- On September 5, 2025, a prospectus supplement was filed for an additional $6,280,000 of Common Stock.
Clene Inc. has amended existing senior secured convertible notes to extend maturity dates and postpone principal repayments, while simultaneously entering into a new $1.5 million senior secured convertible promissory note agreement.
🚩 Red Flags
- Related-party transactions: Kensington (a noteholder and collateral agent) is controlled by Alison Mosca, a board member.
- Liquidity pressure: The company is restructuring debt to postpone massive $1M monthly principal repayments that were looming in early 2026.
- Dilution risk: Both the amended December 2024 notes and new August 2025 notes contain conversion features at a fixed price ($4.44), posing significant dilution risk to existing shareholders.
- High-interest/Penalty terms: The inclusion of a 10% penalty on principal plus interest in the event of default indicates high lender protection requirements.
📋 Key Facts
- Amended December 2024 Notes: Maturity extended from June 20, 2026, to February 13, 2027; monthly $1M principal repayments postponed from Jan 17, 2026, to Sept 13, 2026.
- Interest Treatment: Remaining interest on December 2024 Notes will be capitalized and added to the balance; holders can convert up to 65% of capitalized interest into common stock at $4.44/share.
- New August 2025 Note Purchase Agreement: $1,500,000 in senior secured convertible promissory notes issued at 12% per annum.
- August 2025 Note Terms: Maturity is 18 months from closing or upon Change in Control; monthly principal repayments of $150,000 start in 13 months; holders can convert up to 65% of initial principal at $4.44/share.
- Default Provision: If an event of default occurs, a majority of noteholders can declare the notes due and payable plus a 10% penalty.
Clene Inc. has filed a prospectus supplement under its existing equity distribution agreement with Canaccord Genuity LLC to offer an additional $2,015,000 in common stock. This follows previous sales of approximately $1,713,263 under the same agreement.
🚩 Red Flags
- Continuous dilution: The company is actively utilizing an 'at-the-market' style equity distribution agreement to raise capital, which typically results in ongoing shareholder dilution.
- Reliance on equity financing: Frequent use of placement agents for small tranches suggests a need for immediate liquidity.
📋 Key Facts
- The Company filed a prospectus supplement on July 3, 2025, for an aggregate of $2,015,000 in additional common stock.
- The underlying Equity Distribution Agreement was entered into on April 28, 2025, with Canaccord Genuity LLC as placement agent.
- The total aggregate offering price under the master agreement is up to $25,000,000.
- Approximately $1,713,263 in common stock has been sold prior to this filing.
Clene Inc. issued a regulatory update following a Type C meeting with the FDA regarding its neurofilament biomarker analysis plan. The company also confirmed two additional upcoming meetings with the FDA.
📋 Key Facts
- Held a 'constructive' Type C meeting with the FDA on June 30, 2025.
- The meeting focused on the Company’s neurofilament biomarker analysis plan.
- Confirmed two additional future FDA meetings are scheduled.
Clene Inc. has regained compliance with Nasdaq Listing Rule 5550(b)(2) regarding its market value of listed securities. The company's market value exceeded the $35 million threshold for 10 consecutive business days, ending June 16, 2025.
🚩 Red Flags
- Previous non-compliance with Nasdaq minimum market value requirements indicates historical volatility or liquidity issues.
📋 Key Facts
- The Company regained compliance with Nasdaq Listing Rule 5550(b)(2) on June 17, 2025.
- Compliance was met by maintaining a market value of listed securities of $35.0 million or greater for 10 consecutive business days (June 2, 2025 - June 16, 2025).
- The Nasdaq matter regarding this specific rule is now considered closed.
Clene Inc. reported the results of its 2025 Annual Meeting of Stockholders, which included the election of three directors and ratification of Deloitte & Touche LLP as independent auditors. Additionally, stockholders approved an amendment to the 2020 Stock Plan to increase reserved shares by 800,000.
🚩 Red Flags
- The filing references a prior 1-for-20 reverse stock split from July 2024, indicating historical dilution/capital structure volatility.
📋 Key Facts
- Stockholders approved increasing the number of shares reserved under the Amended 2020 Stock Plan by 800,000 shares on May 22, 2025.
- David J. Matlin, Arjun “JJ” Desai, M.D., and Matthew Kiernan AM, Ph.D., DSc were elected to the Board of Directors.
- Deloitte & Touche LLP was ratified as the independent registered public accounting firm for fiscal year 2025.
- The Board approved an amendment to the Director Compensation Program to adjust equity grants following a previous 1-for-20 reverse stock split (July 11, 2024).
- Named Executive Officer (NEO) compensation was approved on an advisory basis.
Clene Inc. received a notice from Nasdaq stating it is non-compliant with the Minimum Market Value of Listed Securities (MVLS) requirement, having fallen below the $35 million threshold for 30 consecutive business days. The company has until November 3, 2025, to regain compliance or face potential delisting.
🚩 Red Flags
- Delisting notice from Nasdaq (Rule 5550(b)(2))
- Failure to meet alternative listing standards for stockholders' equity and net income
- Market capitalization/MVLS is significantly below the required $35 million threshold
📋 Key Facts
- Received written notice from Nasdaq on May 6, 2025, regarding non-compliance with Nasdaq Listing Rule 5550(b)(2).
- The Market Value of Listed Securities (MVLS) has been below the $35.0 million requirement for the last 30 consecutive business days.
- Company fails alternative standards: stockholders' equity is under $2.5 million and net income was not $500,000 in recent fiscal years.
- The company has a 180-day grace period to regain compliance, expiring on November 3, 2025.
- Company announced Q1 2025 financial results via press release on May 7, 2025.
Clene Inc. entered into an equity distribution agreement with Canaccord Genuity LLC to facilitate the potential sale of up to $25,000,000 in common stock via a registered shelf offering.
🚩 Red Flags
- Potential for significant shareholder dilution through the issuance of up to $25M in new common stock.
- The use of an 'at-the-market' style equity distribution agreement is a common method for micro-cap companies to raise immediate working capital, often at the expense of existing shareholders.
📋 Key Facts
- Agreement date: April 28, 2025
- Placement Agent: Canaccord Genuity LLC
- Aggregate offering amount: Up to $25,000,000 in common stock
- Commission rate: Fixed at 3.0% of gross proceeds
- The sale will be conducted under a previously declared effective Form S-3 registration statement (filed March 24, 2025; effective April 25, 2025).
Clene Inc. announced a presentation of clinical data regarding its CNM-Au8® treatment at the American Academy of Neurology Late-Breaking Science Session. The data focuses on evidence of remyelination and neuronal repair from the long-term open-label extension (LTE) of the Phase 2 VISIONARY-MS clinical trial.
📋 Key Facts
- Presented evidence of remyelination and neuronal repair with CNM-Au8® treatment.
- Data stems from the long-term open-label extension (LTE) of the Phase 2 VISIONARY-MS clinical trial.
- Presentation occurred at the American Academy of Neurology Late-Breaking Science Session on April 8, 2025.
Clene Inc. issued 35,311 shares of common stock at $3.54 per share to settle an outstanding debt of $125,000. The issuance was conducted under a previously effective S-3 registration statement.
🚩 Red Flags
- Debt settlement via equity issuance can indicate liquidity constraints or a preference for preserving cash over diluting shareholders.
📋 Key Facts
- Date of event: March 26, 2025
- Shares issued: 35,311 shares of common stock
- Issuance price: $3.54 per share
- Total debt satisfied: $125,000
- Registration basis: Form S-3 (effective April 26, 2022)
Clene Inc. filed an 8-K to announce its full year operating and financial results for the fiscal year ended December 31, 2024.
📋 Key Facts
- Report date: March 24, 2025
- Reporting period: Full year ended December 31, 2024
- The filing includes a press release (Exhibit 99.1) detailing financial results.
- Information provided under Item 2.02 is furnished, not filed.
Clene Inc. issued an 8-K to announce positive clinical data from a cross-regimen analysis of the HEALEY ALS Platform Trial, indicating a significant survival advantage for CNM-Au8 treatment.
📋 Key Facts
- Announced results from a new cross-regimen analysis of the HEALEY ALS Platform Trial.
- Data shows a 'significant survival advantage' associated with CNM-Au8 treatment.
- The filing is primarily an announcement of clinical trial data via press release (Exhibit 99.1).
Clene Inc. announced a subaward amendment with Columbia University regarding the NIH-funded Expanded Access Program (ACT-EAP) for its CNM-Au8 treatment of ALS. The amendment provides for reimbursement of Company expenses for the second year of the program.
📋 Key Facts
- Entered into Subaward Amendment 1 with Columbia University on January 28, 2025.
- The amendment covers the second year of the ACT-EAP (September 1, 2024, to August 31, 2025).
- Reimbursement for Company expenses under this amendment is capped at $8.0 million.
- The program supports CNM-Au8 treatment for amyotrophic lateral sclerosis (ALS) under the Accelerating Access to Critical Therapies for ALS Act.
Clene Inc. entered into a $10 million senior secured convertible promissory note purchase agreement to refinance existing debt and provide working capital. The transaction involves related parties, including an entity controlled by a board member.
🚩 Red Flags
- Related-party transaction: Kensington Clene 2024 LLC (a purchaser) is controlled by Alison Mosca, a member of the Company's board.
- High interest rate (12% per annum) on new debt.
- Potential dilution via convertible notes and existing warrants with significantly reduced exercise prices ($4.6014 vs original $16.00).
- The company is essentially engaging in a debt rollover/refinancing to avoid immediate default or liquidity crisis.
📋 Key Facts
- Entered into a Note Purchase Agreement on December 17, 2024, for $10,000,000 in senior secured convertible promissory notes.
- Notes bear a 12% per annum interest rate and mature in 18 months (or upon Change in Control).
- Monthly principal repayments of $1,000,000 are scheduled to commence on the 13-month anniversary.
- Conversion price for up to 65% of the principal is set at $5.668 per share.
- Proceeds will be used first to repay approximately $7.9 million in obligations to Avenue Venture Opportunities Fund, L.P., with the remainder for working capital.
- The company successfully terminated its previous Loan and Security Agreement with Avenue on December 20, 2024.
Clene Inc. announced that the FDA has provided a potential regulatory roadmap for accelerated approval of its CNM-Au8 treatment in ALS through the submission of additional biomarker data. The company also updated its corporate presentation and shared clinical trial data regarding long-term survival and neurodegeneration biomarkers.
📋 Key Facts
- FDA provided a potential path for accelerated approval via submission of additional CNM-Au8 biomarker data in ALS.
- Company presented data on long-term survival with 30 mg CNM-Au8 treatment at the 35th International Symposium on ALS/MND (Dec 6-7, 2024).
- Presented data regarding biomarkers of neurodegeneration, astrogliosis, and inflammation.
- Updated corporate presentation released via website.
Clene Inc. filed an 8-K to announce its third quarter 2024 financial results and provide an updated corporate presentation via its website.
📋 Key Facts
- Announced Q3 2024 financial results for the period ended September 30, 2024.
- Released an updated Corporate Presentation on the company's investor relations website (invest.clene.com).
- Filed under Item 7.01 (Regulation FD Disclosure) and Item 2.02 (Results of Operations and Financial Condition).
Clene Inc. presented the preliminary design for its RESTORE-ALS international Phase 3 clinical trial of CNM-Au8 (30 mg) at the 2024 Annual NEALS Meeting.
📋 Key Facts
- Presented preliminary design for RESTORE-ALS, an international Phase 3 clinical trial.
- The trial focuses on CNM-Au8 30 mg dosage.
- Presentation delivered at the 2024 Annual Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) Meeting.
- Filing date: October 23, 2024.
Clene Inc. entered into a Third Amendment to its Loan and Security Agreement with Avenue Venture Opportunities Fund, L.P., which includes modified principal payment schedules and conditional interest-only periods tied to equity fundraising milestones and FDA regulatory progress.
🚩 Red Flags
- Heavy reliance on immediate equity fundraising ($10M milestone by Oct 31) to avoid full principal payments.
- Significant warrant price reduction (from $16.00 to $4.6014), indicating potential dilution and restructuring of debt terms for the lender.
- Debt repayment schedule is heavily contingent on binary regulatory outcomes (FDA NDA milestone).
📋 Key Facts
- The October 1, 2024, principal payment was reduced from $3,333,333.33 to $2,000,000.00.
- An interest-only period (Nov 1 – Dec 31, 2024) is contingent upon raising at least $10M in gross equity proceeds by Oct 31, 2024.
- The company expects its September 2024 equity offering to satisfy the 'September Equity Milestone' of $7M.
- A second interest-only period and deferred amortization are contingent upon an 'ALS NDA Milestone' (FDA non-objection to CNM-Au8 New Drug Application) by Dec 31, 2024.
- The exercise price for the Avenue Warrant was amended/restated from $16.00 per share down to $4.6014 per share.
Clene Inc. announced a multi-tiered financing involving the sale of common stock and various warrants to an institutional investor, existing stockholders, and company insiders. The total expected gross proceeds from all offerings are approximately $7.3 million.
🚩 Red Flags
- Significant dilution via multiple tranches of common stock, pre-funded warrants, and restricted warrants.
- Insider participation (Affiliate Investors) in a private placement alongside institutional investors.
- Lock-up provisions tied to FDA regulatory outcomes, creating uncertainty for liquidity.
- Heavy use of warrants which can lead to significant future dilution upon exercise.
📋 Key Facts
- Entered into an RD Purchase Agreement with an Accredited Investor for 725,000 shares at $4.713/share plus pre-funded warrants.
- Concurrent private placement with Current Investors (existing stockholders) for 257,111 restricted shares and associated warrants.
- Affiliate Purchase Agreements with directors and officers for 122,819 restricted shares at $4.75 per share.
- Total expected gross proceeds: ~$3.5M (RD Agreement) + ~$3.8M (Private Placements) = ~$7.3 million.
- Canaccord Genuity LLC acting as exclusive Placement Agent with a 6.00% cash fee on the RD offering.
- Proceeds intended for clinical development of lead drug candidate CNM-Au8 and general corporate purposes.
Clene Inc. announced it has been granted an in-person meeting with senior FDA leadership to discuss biomarker and clinical/survival data for its product candidate, CNM-Au8.
📋 Key Facts
- The company was granted an in-person meeting with U.S. Food and Drug Administration (FDA) senior leadership.
- Meeting topic: Discussion of CNM-Au8 biomarker and related clinical and survival data.
- Announcement date: September 16, 2024.
Clene Inc. filed an 8-K to announce its second quarter 2024 financial results and recent operating highlights for the period ended June 30, 2024.
📋 Key Facts
- Reporting date: August 7, 2024
- Period covered: Second Quarter 2024 (ended June 30, 2024)
- The filing is primarily a placeholder to furnish the press release containing financial results via Exhibit 99.1.
- Company ticker: CLNN (Nasdaq Capital Market)
Clene Inc. issued an 8-K to announce the submission of new CNM-Au8 biomarker and clinical efficacy data to the FDA regarding the treatment of ALS. The company also updated its corporate presentation.
📋 Key Facts
- Submitted new CNM-Au8 biomarker and clinical efficacy data to the FDA on August 6, 2024.
- The data is intended to support the treatment of amyotrophic lateral sclerosis (ALS).
- Updated the company's corporate presentation via its website (invest.clene.com).
Clene Inc. has regained compliance with Nasdaq's minimum bid price requirement. The company successfully maintained a closing bid price of $1.00 or greater for 10 consecutive business days, resolving the previous delisting risk.
🚩 Red Flags
- Historical volatility/price weakness that necessitated a compliance notice in the first place.
📋 Key Facts
- The Company received notice from Nasdaq on July 25, 2024, regarding compliance with Listing Rule 5550(a)(2).
- Compliance was achieved by maintaining a closing bid price of at least $1.00 per share for 10 consecutive business days (July 11, 2024 - July 24, 2024).
- The delisting matter is officially considered closed.
Clene Inc. announced plans to submit a briefing book to the FDA regarding its drug candidate CNM-Au8 for the treatment of ALS. The submission follows a granted Type C interaction aimed at obtaining feedback on an accelerated approval pathway.
📋 Key Facts
- Company is seeking FDA feedback via a Type C interaction.
- The focus is on establishing a potential regulatory pathway for accelerated approval of CNM-Au8.
- Target indication: Amyotrophic lateral sclerosis (ALS).
- Filing date: July 11, 2024.
Clene Inc. has announced a 1-for-20 reverse stock split effective July 11, 2024. This action will reduce the total number of issued and outstanding shares from approximately 128.7 million to approximately 6.4 million.
🚩 Red Flags
- Reverse stock split: Often used to combat low share prices and mitigate delisting risks or attract institutional investors.
- Significant reduction in share count (95% reduction) which can lead to increased volatility.
📋 Key Facts
- Reverse split ratio: 1-for-20
- Effective Date: July 11, 2024, at 12:01 a.m. ET
- Pre-split shares outstanding: ~128.7 million
- Post-split shares outstanding: ~6.4 million
- New CUSIP number for Common Stock: 185634201
- Warrants (CLNNW) will not change CUSIP but will be adjusted accordingly
- Fractional shares will be paid out in cash based on the closing price from the trading day preceding effectiveness
Clene Inc. announced the presentation of clinical data from its HEALEY ALS Platform Trial open label extension (OLE) at the 2024 ENCALS Meeting. The disclosure includes extended survival data and neurofilament light (NfL) responder results for CNM-Au8 treatment.
📋 Key Facts
- Presented a poster at the 2024 ENCALS Meeting regarding clinical results of CNM-Au8 in the HEALEY ALS Platform Trial OLE.
- Data includes extended survival data through 3.5 years.
- Includes new neurofilament light (NfL) responder results with CNM-Au8 30 mg treatment.
Clene Inc. held its 2024 Annual Meeting of Stockholders where shareholders approved several significant structural changes, including a massive increase in authorized shares and authorization for a reverse stock split.
🚩 Red Flags
- Authorization of a reverse stock split (ratio between 1-for-5 and 1-for-20) often indicates a need to boost share price to meet exchange listing requirements.
- Significant increase in authorized shares (doubled from 300M to 600M) suggests potential future dilution through equity offerings.
📋 Key Facts
- Stockholders approved an amendment to the Certificate of Incorporation to increase authorized Common Stock from 300,000,000 to 600,000,000 shares.
- Stockholders approved increasing the number of shares reserved for issuance under the Amended 2020 Stock Plan by 30,000,000 shares.
- Stockholders authorized a reverse stock split with a ratio between 1-for-5 and 1-for-20, to be determined by the Board.
- Three directors (Jonathon T. Gay, Vallerie V. McLaughlin, M.D., and Reed N. Wilcox) were elected to Class I director terms ending in 2027.
- Deloitte & Touche LLP was ratified as the independent registered public accounting firm for fiscal year 2024.
Clene Inc. filed an 8-K to announce its first quarter 2024 financial results and operating highlights for the period ended March 31, 2024.
📋 Key Facts
- Reported date of event: May 8, 2024
- Reporting period: Quarter ended March 31, 2024
- The filing includes a press release (Exhibit 99.1) regarding Q1 2024 financial results and operating highlights.
Clene Inc. entered into amended and restated exclusive supply and license agreements with 4Life Research, LLC, a stockholder and related party. The agreements extend through 2033 and involve minimum sales commitments and royalty structures.
🚩 Red Flags
- Related-party transaction with a major stockholder (4Life Research, LLC).
- Long-term dependency on a single related party for revenue via exclusive supply and license agreements through 2033.
- Potential for restricted market access due to exclusivity clauses, though mitigated by the 2027 non-exclusivity provision.
📋 Key Facts
- Amended Supply Agreement: 4Life (or affiliates) to purchase dietary supplements exclusively from the Company at cost plus 20%.
- Minimum Sales Commitment: 4Life must meet specific sales targets for years 2024 through 2033.
- License Agreement: 4Life receives an exclusive, royalty-bearing license (3% of incremental sales) to commercialize Licensed Products.
- Exclusivity Provision: Exclusivity can be lost if 4Life fails minimum sales commitments for two consecutive years or fails to pay additional royalties.
- Non-exclusivity Trigger: On or after January 1, 2027, the Company is permitted to sell products through third-party retail outlets or its own websites regardless of exclusivity terms.
Clene Inc. released clinical data from its VISIONARY-MS trial long-term extension (LTE) regarding CNM-Au8 for the treatment of multiple sclerosis (MS). The findings were presented at the 2024 American Academy of Neurology (AAN) Annual Meeting.
📋 Key Facts
- Company released clinical results from the VISIONARY-MS trial long-term extension (LTE).
- The data focuses on CNM-Au8 as a treatment for repair and remyelination in Multiple Sclerosis (MS).
- Results were presented during the Emerging Science Session at the 2024 American Academy of Neurology (AAN) Annual Meeting.
- Information was disclosed via presentation, poster, and press release on April 16, 2024.
Clene Inc. entered into a grant subaward agreement with Columbia University on April 3, 2024, as part of a larger $45.1 million NIH grant. The subaward provides reimbursement for expenses related to an Expanded Access Program (EAP) for the treatment of ALS.
📋 Key Facts
- Entered into a Subaward agreement with Columbia University on April 3, 2024.
- The subaward is part of a larger $45.1 million NIH grant awarded to Columbia/Synapticure/Clene.
- Subaward provides reimbursement for expenses up to $7.3 million for the period Sept 25, 2023, to Aug 31, 2024.
- Total potential subawards to Clene under the full NIH grant may reach $30.9 million through August 31, 2027.
- Clene retains ownership of its 'Background IP' developed at private expense prior to the subaward.
Clene Inc. filed an 8-K to announce its full year operating and financial results for the fiscal year ended December 31, 2023.
📋 Key Facts
- The filing is a standard announcement of annual operating and financial results (Item 2.02).
- Report date: March 13, 2024.
- Reporting period: Year ended December 31, 2023.
- The company's common stock trades on the Nasdaq Capital Market under ticker CLNN.
Clene Inc. issued an 8-K to announce the presentation of clinical results from its VISIONARY-MS trial long-term extension (LTE) at the ACTRIMS Forum 2024. The filing includes a presentation regarding CNM-Au8 30mg treatment for multiple sclerosis.
📋 Key Facts
- Company presented clinical results for CNM-Au8 30mg treatment from the VISIONARY-MS trial long-term extension (LTE).
- The presentation was delivered at the Americas Committee for Treatment and Research in MS (ACTRIMS) Forum 2024.
- Filing date: February 29, 2024.
Clene Inc. issued an 8-K to announce positive clinical observations regarding its CNM-Au8 treatment, specifically noting a significant survival benefit in patients within its ALS compassionate use expanded access programs (EAPs). The company provided supplemental presentation materials and a press release detailing these findings.
📋 Key Facts
- Reported 'significant survival benefit' for CNM-Au8 treatment in ALS EAP compassionate use programs.
- The announcement was made via a press release and a presentation on the company website (invest.clene.com).
- Filing date: February 22, 2024.
Clene Inc. received a notice from Nasdaq granting an additional 180-day period to regain compliance with the Minimum Bid Price Requirement ($1.00 per share). The company must meet this requirement by July 29, 2024, or face potential delisting.
🚩 Red Flags
- Delisting notice/non-compliance with minimum bid price requirement
- Explicit mention of potential reverse stock split to maintain listing
- Failure to meet compliance within the first 180-day window
📋 Key Facts
- The Company failed to regain compliance with Nasdaq Listing Rule 5550(a)(2) within the initial 180-day period ending January 29, 2024.
- Nasdaq has granted an additional 180-day extension until July 29, 2024.
- Compliance can be achieved if the stock closes at $1.00 or more for 10 consecutive business days.
- The Company explicitly mentioned it may use a reverse stock split to cure the deficiency.
Clene Inc. issued an 8-K to provide an updated corporate presentation and a press release regarding positive clinical trial results for its CNM-Au8 treatment.
📋 Key Facts
- Released an updated Corporate Presentation on January 8, 2024.
- Announced significant improvement in vision and cognition with CNM-Au8 treatment in the VISIONARY-MS trial long-term open label extension.
- The company is classified as an emerging growth company.